Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.71 |
| ▸ | CCR9 | P51686 | 4/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212911 | 0.89 | CCR2 (0.64) | CCR2CCR9ABCB11 | |
| SCHEMBL4655319 | 0.88 | CCR2 (0.67) | CCR2CCR9 | |
| SCHEMBL4371922 | 0.87 | CCR2 (0.75) | CCR2CCR9ABCB11PTGS2KDM4E | |
| SCHEMBL4541643 | 0.86 | CCR2 (0.77) | CCR2CCR9ABCB11PTGS2KDM4E | |
| SCHEMBL9536869 | 0.86 | CCR2 (0.76) | CCR2CCR9ABCB11PTGS2KDM4E | |
| SCHEMBL4214845 | 0.85 | CCR9 (0.59) | CCR2CCR9ABCB11 | |
| SCHEMBL4205357 | 0.85 | PPARG (0.61) | CCR2CCR9ABCB11 | |
| SCHEMBL4206942 | 0.85 | CCR2 (0.68) | CCR2CCR9ABCB11 | |
| SCHEMBL13802525 | 0.85 | CCR2 (0.71) | CCR2CCR9ABCB11 | |
| SCHEMBL4201841 | 0.83 | CCR2 (0.77) | CCR2CCR9ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CCR2 1386/4885CCR9 2109/4885ABCB11 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.